Amgen is recalling nearly 944,142 bottles of two critical medications—Corlanor (ivabradine) and Sensipar (cinacalcet)—after the FDA confirmed the presence of a “foreign substance” on some tablets, a Class II recall announced June 26, 2026. The contamination, found during routine inspections, poses a low risk to patients but has triggered a nationwide pullback of lots distributed between October 2021 and December 2028.
Why the Recall Happened: A Manufacturing Glitch with Low Risk
The FDA and California state pharmacy officials confirmed the issue stems from “unexpected foreign matter” localized on the exterior of tablets processed in Amgen’s Building 23 packaging area. According to the California Board of Pharmacy, hazard assessments determined the risk to patients is “low,” with no reported illnesses linked to the contamination. The recall covers Corlanor—used to treat chronic heart failure—and Sensipar, which manages overactive parathyroidism in kidney disease patients.
The FDA classified this as a Class II recall, meaning the affected medications “could cause temporary or medically reversible adverse health consequences” but do not pose a serious risk. While no complaints have been reported, the agency emphasized the precautionary measure to ensure patient safety.
The Scope of the Recall: Which Lots Are Affected?
The recall includes specific lot codes and expiration dates for both medications, with the affected batches spanning from 2021 through 2028. For example, Corlanor 5-mg tablets (NDC 55513-800-60) cover expiration dates ranging from October 2026 to December 2028, while Sensipar 30-mg tablets (NDC 55513-073-30) expire in December 2027. The full list of impacted lots, provided by the FDA, includes over 40 distinct lot codes across both drugs.
| Medication | Strength | Packaging | Lot Codes | Expiration Dates |
| Corlanor (ivabradine) | 5 mg | 60 tablets | 1138201, 1138202, 1138900, etc. | Oct 2026 – Dec 2028 |
| Sensipar (cinacalcet) | 30 mg | 30 tablets | 1156858 | Dec 2027 |
| Corlanor (ivabradine) | 7.5 mg | 60 tablets | 1138203, 1142065, etc. | Jul 2026 – Aug 2028 |
Patients holding recalled medications should contact their pharmacies for replacements or refunds. The FDA advises checking the lot code and expiration date on medication bottles to determine if they fall under the recall.
What This Means for Patients: Low Risk, but Precautionary Action
The FDA’s classification of this as a Class II recall reflects its assessment that the foreign substance—while unexpected—does not pose a significant health threat. “The overall patient safety risk is low,” officials noted, emphasizing that the contamination is confined to the tablet’s exterior coating. However, the agency’s decision to issue a recall underscores its commitment to maintaining rigorous manufacturing standards, particularly after recent high-profile drug safety issues.
For context, Amgen’s stock (AMGN) has faced scrutiny in recent years over manufacturing quality, including a 2024 FDA warning letter citing deviations in its sterile drug production. While this recall does not directly reference that prior action, it adds to a pattern of heightened regulatory oversight in the pharmaceutical industry.
Next Steps: What Patients and Providers Should Do
Patients currently using the recalled medications should not discontinue treatment abruptly but should instead verify their lot codes with their pharmacies or healthcare providers. The FDA recommends returning or disposing of affected bottles and obtaining replacements. Providers are advised to check the FDA’s recall database for updates and to ensure patients receive unaffected supplies.
The recall process typically takes weeks to complete, with Amgen working to distribute replacements and address the root cause of the contamination. While the immediate health risk is minimal, the incident serves as a reminder of the pharmaceutical industry’s ongoing challenges in maintaining flawless manufacturing standards—especially as demand for critical medications like Corlanor and Sensipar continues to rise.
Broader Implications: Trust in Drug Manufacturing Under Scrutiny
This recall comes amid growing concerns about drug manufacturing quality in the U.S. The FDA has increasingly focused on preventing contamination and ensuring compliance with Current Good Manufacturing Practice (CGMP) regulations. In 2024 alone, the agency issued over 100 warning letters to pharmaceutical companies for similar issues, signaling a shift toward stricter enforcement. For Amgen, this recall—though low-risk—could further pressure the company to demonstrate improved quality control, particularly in its high-profile cardiac and renal drug lines.
Industry analysts note that such recalls, while rare for high-value drugs like Corlanor and Sensipar, are not unprecedented. For example, in 2025, Pfizer recalled a batch of blood pressure medication due to a similar foreign substance issue, though that incident also carried a low-risk classification. The key difference here is the scale: Amgen’s recall affects nearly a million bottles, a volume that underscores the potential reach of manufacturing errors in today’s global supply chain.
For patients, the takeaway is clear: vigilance is required. While the risk from this recall is minimal, it highlights the importance of regularly checking medication labels and staying informed about recalls. The FDA’s recall database remains the most reliable source for updates, and patients with concerns should consult their healthcare providers.
